New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

Sherry X. Yang, Eric Polley, Stanley Lipkowitz

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations and AKT activation by phosphorylation (pAKT) are often detected in many cancers and especially at high frequencies in breast cancer. Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant outcomes in estrogen receptor-positive (ER+) early stage breast cancer and tend to be with worse prognosis in ER- disease. pAKT expression has been identified to predict paclitaxel chemotherapy benefit in node-positive breast cancer. Preclinical and neoadjuvant trial data suggest that PIK3CA alterations confer resistance to HER2-targeted therapy and are associated with lower pathological complete response (pCR) rate in HER2-positive breast cancer. However, recent results from randomized clinical trials of adjuvant and metastatic settings show that patients with mutant and wildtype PIK3CA tumors derived similar benefit from anti-HER2 therapy. This article, with our new insights, aims to decipher the mixed data and discusses the influence of the potential confounding factors in the assessments. We also share our views for validation of PI3K/AKT alterations in relation to clinical outcome in the context of specific breast cancer subtypes and treatment modalities towards further advance of the precision medicine for breast cancer treatment.

Original languageEnglish (US)
Pages (from-to)87-96
Number of pages10
JournalCancer Treatment Reviews
Volume45
DOIs
StatePublished - Apr 1 2016

Fingerprint

Critical Pathways
Phosphatidylinositol 3-Kinases
Breast Neoplasms
Precision Medicine
Mutation
Therapeutics
Paclitaxel
Estrogen Receptors
Neoplasms
Carcinogenesis
Randomized Controlled Trials
Phosphorylation
Drug Therapy
Survival

Keywords

  • Breast cancer
  • Chemotherapy
  • HER2
  • Paclitaxel
  • PAKT
  • PIK3CA mutations

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. / Yang, Sherry X.; Polley, Eric; Lipkowitz, Stanley.

In: Cancer Treatment Reviews, Vol. 45, 01.04.2016, p. 87-96.

Research output: Contribution to journalArticle

@article{427e93accee84df592d1700f30045f6f,
title = "New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer",
abstract = "PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations and AKT activation by phosphorylation (pAKT) are often detected in many cancers and especially at high frequencies in breast cancer. Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant outcomes in estrogen receptor-positive (ER+) early stage breast cancer and tend to be with worse prognosis in ER- disease. pAKT expression has been identified to predict paclitaxel chemotherapy benefit in node-positive breast cancer. Preclinical and neoadjuvant trial data suggest that PIK3CA alterations confer resistance to HER2-targeted therapy and are associated with lower pathological complete response (pCR) rate in HER2-positive breast cancer. However, recent results from randomized clinical trials of adjuvant and metastatic settings show that patients with mutant and wildtype PIK3CA tumors derived similar benefit from anti-HER2 therapy. This article, with our new insights, aims to decipher the mixed data and discusses the influence of the potential confounding factors in the assessments. We also share our views for validation of PI3K/AKT alterations in relation to clinical outcome in the context of specific breast cancer subtypes and treatment modalities towards further advance of the precision medicine for breast cancer treatment.",
keywords = "Breast cancer, Chemotherapy, HER2, Paclitaxel, PAKT, PIK3CA mutations",
author = "Yang, {Sherry X.} and Eric Polley and Stanley Lipkowitz",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.ctrv.2016.03.004",
language = "English (US)",
volume = "45",
pages = "87--96",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

AU - Yang, Sherry X.

AU - Polley, Eric

AU - Lipkowitz, Stanley

PY - 2016/4/1

Y1 - 2016/4/1

N2 - PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations and AKT activation by phosphorylation (pAKT) are often detected in many cancers and especially at high frequencies in breast cancer. Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant outcomes in estrogen receptor-positive (ER+) early stage breast cancer and tend to be with worse prognosis in ER- disease. pAKT expression has been identified to predict paclitaxel chemotherapy benefit in node-positive breast cancer. Preclinical and neoadjuvant trial data suggest that PIK3CA alterations confer resistance to HER2-targeted therapy and are associated with lower pathological complete response (pCR) rate in HER2-positive breast cancer. However, recent results from randomized clinical trials of adjuvant and metastatic settings show that patients with mutant and wildtype PIK3CA tumors derived similar benefit from anti-HER2 therapy. This article, with our new insights, aims to decipher the mixed data and discusses the influence of the potential confounding factors in the assessments. We also share our views for validation of PI3K/AKT alterations in relation to clinical outcome in the context of specific breast cancer subtypes and treatment modalities towards further advance of the precision medicine for breast cancer treatment.

AB - PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations and AKT activation by phosphorylation (pAKT) are often detected in many cancers and especially at high frequencies in breast cancer. Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant outcomes in estrogen receptor-positive (ER+) early stage breast cancer and tend to be with worse prognosis in ER- disease. pAKT expression has been identified to predict paclitaxel chemotherapy benefit in node-positive breast cancer. Preclinical and neoadjuvant trial data suggest that PIK3CA alterations confer resistance to HER2-targeted therapy and are associated with lower pathological complete response (pCR) rate in HER2-positive breast cancer. However, recent results from randomized clinical trials of adjuvant and metastatic settings show that patients with mutant and wildtype PIK3CA tumors derived similar benefit from anti-HER2 therapy. This article, with our new insights, aims to decipher the mixed data and discusses the influence of the potential confounding factors in the assessments. We also share our views for validation of PI3K/AKT alterations in relation to clinical outcome in the context of specific breast cancer subtypes and treatment modalities towards further advance of the precision medicine for breast cancer treatment.

KW - Breast cancer

KW - Chemotherapy

KW - HER2

KW - Paclitaxel

KW - PAKT

KW - PIK3CA mutations

UR - http://www.scopus.com/inward/record.url?scp=84960946714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960946714&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.03.004

DO - 10.1016/j.ctrv.2016.03.004

M3 - Article

C2 - 26995633

AN - SCOPUS:84960946714

VL - 45

SP - 87

EP - 96

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -